Literature DB >> 2294984

Intact transferrin receptors in human plasma and their relation to erythropoiesis.

H A Huebers1, Y Beguin, P Pootrakul, D Einspahr, C A Finch.   

Abstract

Intact transferrin receptor molecules complexed with transferrin were found in human plasma. The concentration of receptors was determined by an enzyme-linked immunosorbent assay that uses polyclonal antibodies. The mean concentration of 8,279 micrograms/L in 56 normal adults appears to be unrelated to age or sex. Additional receptor measurements were performed on plasmas from 260 subjects with erythropoietic disorders. Decreased concentration of plasma receptors was found in patients with erythroid hypoplasia and increased numbers in those with erythroid hyperplasia. Ferrokinetic measurements of erythropoiesis were compared with numbers of receptors in 148 subjects, and a close correlation was found (r = .86). Both sets of values, measured in different conditions and expressed in relation to normal, were consistent with expected values. Receptor values were unproportionally increased only in conditions of iron deficiency. It is concluded that plasma receptors have a constant relationship to tissue receptors, and their number in most instances reflects the rate of erythropoiesis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2294984

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  32 in total

1.  The future of doping control in athletes. Issues related to blood sampling.

Authors:  K I Birkeland; P Hemmersbach
Journal:  Sports Med       Date:  1999-07       Impact factor: 11.136

2.  Pathologic conditions associated with elevated plasma soluble transferrin receptor levels in elderly iron replete anemic patients.

Authors:  Torbjörn Karlsson
Journal:  Int J Hematol       Date:  2010-04-14       Impact factor: 2.490

3.  The difference between fingerstick and venous hemoglobin and hematocrit varies by sex and iron stores.

Authors:  Ritchard G Cable; Whitney R Steele; Russell S Melmed; Bryce Johnson; Alan E Mast; Patricia M Carey; Joseph E Kiss; Steven H Kleinman; David J Wright
Journal:  Transfusion       Date:  2011-10-20       Impact factor: 3.157

4.  The importance of serum transferrin receptor level in the diagnosis of functional iron deficiency due to recombinant human erythropoietin treatment in haemodialysis patients.

Authors:  H Z Tonbul; H Kaya; N Y Selçuk; S B Tekin; A San; F Akçay; E Akarsu
Journal:  Int Urol Nephrol       Date:  1998       Impact factor: 2.370

Review 5.  Transferrin receptor in tissue and serum: updated clinical significance of soluble receptor.

Authors:  Yutaka Kohgo; Yoshihiro Torimoto; Junji Kato
Journal:  Int J Hematol       Date:  2002-10       Impact factor: 2.490

6.  Elevated levels of miR-210 correlate with anemia in β-thalassemia/HbE patients.

Authors:  Panjaree Siwaponanan; Suthat Fucharoen; Pornpan Sirankapracha; Pranee Winichagoon; Tsukuru Umemura; Saovaros Svasti
Journal:  Int J Hematol       Date:  2016-06-06       Impact factor: 2.490

7.  Evidence that the expression of transferrin receptor 1 on erythroid marrow cells mediates hepcidin suppression in the liver.

Authors:  Siobán B Keel; Raymond Doty; Li Liu; Elizabeta Nemeth; Sindhu Cherian; Tomas Ganz; Janis L Abkowitz
Journal:  Exp Hematol       Date:  2015-03-14       Impact factor: 3.084

8.  Soluble transferrin receptor and depth of bone marrow suppression following high dose chemotherapy.

Authors:  Sant-Rayn Pasricha; Poyap Rooney; Hans Schneider
Journal:  Support Care Cancer       Date:  2009-01-28       Impact factor: 3.603

9.  Crosstalk between Iron Metabolism and Erythropoiesis.

Authors:  Huihui Li; Yelena Z Ginzburg
Journal:  Adv Hematol       Date:  2010-06-10

10.  Hepcidin/Ferritin Quotient Helps to Predict Spontaneous Recovery from Iron Loss following Blood Donation.

Authors:  Ramin Lotfi; Christine Kroll; Dietmar Plonné; Bernd Jahrsdörfer; Hubert Schrezenmeier
Journal:  Transfus Med Hemother       Date:  2015-11-03       Impact factor: 3.747

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.